Transcranial direct-current stimulation is in a unique regulatory and editorial position: one device (Flow Neuroscience FL-100) holds FDA premarket approval (PMA) for major depressive disorder; every other consumer tDCS device — Caputron, foc.us, theBrainDriver, PlatoScience, LIFTiD — ships under general-wellness for cognitive enhancement, mood, or focus. The same hardware (a constant-current generator and electrodes) carries dramatically different regulatory weight depending on the claim and the clinical evidence behind it. Consumers who confuse the two end up with the wrong product for the wrong indication.
What We Compare
Every tDCS device in our comparison is evaluated on:
FDA / regulatory status decoded — PMA cleared (Flow), 510(k) for specific indication, or general-wellness. We name approval numbers where they exist.
Current output and electrode configuration — milliamps delivered, anode/cathode placement, electrode size. Affects which protocols the device supports.
Clinical evidence audit — sham-controlled RCTs vs open-label vs marketing-only. Flow has a published Nature Medicine RCT (n=174); most consumer wellness tDCS has no comparable evidence.
Prescription gating — Flow FL-100 is prescription-only in the US. Most other tDCS sells direct-to-consumer.
Treatment commitment — session length, daily/weekly cadence, total weeks to a typical protocol.
Safety features — current ramping, automatic shutoff, electrode contact monitoring.
Key Findings (2026)
Flow Neuroscience FL-100 is the only FDA-PMA tDCS device for depression in the US. PMA P230024 was granted in December 2025 based on a published RCT (n=174, Nature Medicine) showing 77% clinical improvement and 57% remission. This is the only consumer tDCS with a disease-treatment claim that the FDA has cleared.
Consumer wellness tDCS (Caputron, foc.us, theBrainDriver) markets cognitive enhancement, not depression treatment. These devices ship under general-wellness without FDA disease-claim clearance. They may be physically similar in current delivery, but the regulatory pathway and intended use are different.
The published cognitive-enhancement tDCS literature is mixed. Memory, working-memory, and learning-task improvements have been reported; effect sizes are small and heterogeneous, with frequent failure-to-replicate. Treat consumer-tDCS cognitive claims as exploratory.
Side effects are real and reported. Flow’s clinical trial documented forehead burning sensation, headaches, and rare worsening mood. Consumer wellness devices report similar frequency. Skin sensitivity at electrode sites is the most common complaint.
Current output, not marketing copy, determines what the device is doing. Most consumer tDCS delivers 1–2 mA; Flow’s protocol is 2 mA. Devices that deliver only 0.5 mA or that don’t sustain stable current are unlikely to produce the published clinical effects.
Who Should Read This
Patients (with prescriber) considering Flow Neuroscience for depression
Buyers researching consumer tDCS for cognitive enhancement (with realistic expectations)
Researchers needing programmable current output and electrode configurations
Anyone trying to understand why one tDCS device is FDA-PMA and another is “general wellness”